Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112021 · ClinicalTrials.gov registry record · Phase 2
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT00112021 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 400 participants.
The verdict
NCT00112021, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
Interventions
- DRUG pramlintide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-05 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112021
The ClinicalTrials.gov registry entry for NCT00112021 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pramlintide acetate is the first listed.
NCT00112021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00112021 about?
NCT00112021 is a clinical study titled "A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects". This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
What is the current status of trial NCT00112021?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2005-05. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00112021?
The interventions under investigation include: pramlintide acetate (DRUG).
Who is sponsoring clinical trial NCT00112021?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.